



Atara Biotherapeutics
Investor Relations Department
701 Gateway Blvd, Suite 200
South San Francisco, CA 94080
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ATRA

| | |
|---------------|---|
| Last Trade: | 15.65 |
| Trade Time: | 4:00 PM ET Sep 22, 2017 |
| Change: | 0.10 ▲ (+0.643%) |
| Day Range | 15.20 - 15.83 |
| 52-Week Range | 11.80 - 23.00 |
| Volume | 192,906 |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Atara Biotherapeutics is a leading "Off-the-Shelf" T-cell immunotherapy company developing products for patients with cancer and Multiple Sclerosis (MS). The company was founded in 2012, and since 2014 the company's stock has been publicly traded on Nasdaq under the symbol ATRA.

Atara's most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-... [\(more\)](#))

Stock Performance



Press Releases [\[View all \]](#)

Sep 11, 2017

[Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129](#)

Sep 5, 2017

[Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230](#)

Aug 31, 2017

[Atara Biotherapeutics to Participate in Three Upcoming Investor Conferences](#)

Aug 22, 2017

[Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Upcoming Events [\[View all \]](#)

Sep 25, 2017

[Cell & Gene Therapy CEO](#)

Sep 26, 2017 4:35 PM ET

[Cantor Fitzgerald Healthcare Conference](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 9, 2017

[Annual Report \(10-K\)](#)

Apr 25, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)